New sophisticated and sensitive injectable drugs require a new generation of custom-tailored pharmaceutical primary packaging. Gerresheimer is combining its expertise into a specialized team called Gx Solutions, an interdisciplinary expert and sales team able to utilize the development know-how of four Technical Competence Centers. The result is new packaging solutions for sensitive agents, enabling safe administration and more efficient drug delivery systems. Gx Solutions particularly also offers tailored services for biotechnologically manufactured medications and for smaller and medium-sized biotech companies. At the PDA in Orlando at the Hotel Loews Royal Pacific on 8 and 9 October, the team of experts will be on hand to speak to trade visitors for two days at booth 709.

Innovative medications are opening up new treatment options for illnesses, which were previously essentially untreatable. Agents are frequently produced using biotechnological means and utilize highly complex, protein-based molecules for the treatment of cancer, neurological conditions and eye diseases. This makes these new medications so sensitive that they require a new generation of pharmaceutical primary packaging, such as prefillable syringes, vials and cartridges, to be reliably effective. As a result, medications and packaging are increasingly being developed simultaneously through joint efforts of pharmaceutical companies and packaging manufacturers to create an ideal comprehensive solution quickly and economically.

Gerresheimer is meeting this trend with a new internationally positioned team of experts. “With Gx Solutions, we have assembled an interdisciplinary team of specialists offering development expertise, international development capabilities and global regulatory expertise,” said Andreas Schütte, (member of the Management Board and responsible for the Plastics & Devices division at Gerresheimer AG). This team of experts no longer thinks in terms of product groups or materials like plastics and glass for its work, but rather develops comprehensive solutions perfectly matched to the requirements of specific markets, applications and patient groups. “Gx Solutions is able to utilize more than 430 product designers, engineers, technicians and skilled workers in the fields of plastics and glass at our Technical Competence Centers in Germany, the US and China,” explained Manfred Baumann (Global Executive Vice of President Sales & Marketing, Administration & TCC, Management Board) at Gerresheimer Regensburg GmbH). “The unit has everything from a quality laboratory to special machine construction to small-batch production at its disposal, which we are able to utilize to produce samples for clinical testing. Thanks to our small-batch production capabilities for syringes, vials and cartridges, which will be established in Q3 2019, we will be able to respond to customer wishes quickly and flexibly.”

One area of Gx Solutions’ activity is the development of primary packaging, which interacts as little as possible with the medications it is filled with. Special patented technologies for cone forming and interior coating have been developed for the prefillable Gx RTF syringes, for example. This makes it possible to offer Gx RTF syringes in silicone oil-reduced and metal-free versions. Prefillable syringes made of new and innovative materials like COP (Cyclic Olefin Polymer) plastics can also be produced. Solutions for increasing user safety and user friendliness, such as especially break-proof packaging, safety systems like Gx InnoSafe for the prevention of needle stick injuries and primary packaging for patients with limited motor capabilities are also important. A third area of activity of Gx Solutions is packaging concepts, which are ideally matched to the development and production processes used by pharmacists. With Gerresheimer Gx RTF vials in the Ompi EZ-fill packaging format, identically packaged sterile injection bottles can be obtained from two different manufacturers.

Gerresheimer will also showcase its products and services at CPhI Worldwide in Madrid from October 9.-11 at the Ifema fairground hall 4, booth C30.

Über die Gerresheimer AG

Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With our plants in Europe, North America, South America, and Asia, we generate revenues of approximately EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: Insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles, and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Firmenkontakt und Herausgeber der Meldung:

Gerresheimer AG
Klaus-Bungert-Straße 4
40468 Düsseldorf
Telefon: +49 (211) 6181-00
Telefax: +49 (211) 6181-295

Marion Stolzenwald
Senior Manager Corporate Communication
Telefon: +49 (211) 6181-246
Fax: +49 (211) 6181-28246
Karin Fischer
Gerresheimer Regensburg GmbH
Telefon: +49 (9431) 639-6140
Fax: +49 (9431) 79838-6140
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.